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The esteemed British Medical Journal (BMJ) devoted a
substantial amount of column space last May 1 to pon-
der upon the relations between physicians, researchers
and the pharmaceutical industry. Amongst others, a
meta-analysis of the publication of results of medical re-
search sponsored by the pharmaceutical industry.2
The involution of the pharmaceutical industry and
physicians is a global phenomenon. The truth of the
matter is that all the medicines developed over the last
60 years have been developed and produced specifically
by the pharmaceutical industry. It is just as obvious that
the research and development of medicines would not
have been possible, nor is it now, without the co-opera-
tion of medical experts, whether they are research scien-
tists or clinical practitioners.
The co-operation and involvement becomes prob-
lematic, when the pharmaceutical industry’s research,
public relations (with, patient organisations, amongst
others), sales promotion, dissemination of information,
or marketing, has undesirable effects on the community.
Examples of this include undermining the public’s confi-
dence in the independence of medical prescribing, dis-
torting the results of medical research and their publica-
tion, and the practices censured by the society, including
the giving, requesting and accepting of benefits and
gifts. 
A particularly disconcerting finding of the above-
mentioned analysis is, that research funded by the phar-
maceutical industry more often than not leads to results
favouring the medicines of the sponsoring manufacturer,
as opposed to research funded from other sources. This
could not be explained away by the quality of the re-
search. It was surmised that the phenomenon was based
on the selection of inappropriate  comparator products
or dosages thereof, and  publication bias.
It is estimated that there are about 80 000 company
representatives in the United States of America, whose
activities were funded to the tune of 19 billion dollars
by the pharmaceutical industry’s sales promotion funds
in the year 2001 alone.3 In Finland, this phenomenon
exists on a totally different scale. Nonetheless, here we
have had to clarify the borderline between the forbidden
and the acceptable in various contexts in cases related
to sponsored travel for physicians, or goods supplied
gratuitously to them.4
Legislation, supervision by the authorities, and self-
regulation by various parties have been tightened, and
the same can also be done in the future. More impor-
tantly, a code of conduct suitable for the Finnish com-
munity and applicable to the whole pharmaceutical field
needs to be developed to cover the various kinds of
dealing and transacting, whereby transparency would be
emphasised. The number of problem situations would
be reduced if transparency in co-operation, including
the funding of projects, were increased. 
1 BMJ Volume 326, 31 May 2003.
2 Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical
industry sponsorship and research outcome and quality: sys-
tematic review. BMJ 326: 1167-1170, 2003.
3 United States General Accounting Office. Prescription drugs:
FDA oversight of direct-to-consumer advertising has limita-
tions. GAO-03-177. October 2002. www.gao.gov/
4 National Board of Medicine 24.6.1985, Record no.
6508/03/82; National Board of Medicine 5.2.2001, Record no.
1261/63/2000; Parliamentary Ombudsman 30.12.2002, Record
no. 1082/2/99.
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The related factors may be associat-
ed with lifestyle and diet, structural
causes, certain medications, and en-
docrine, metabolic and neurological
diseases (Table 1). Onset or exacer-
bation of discomfort caused by con-
stipation associated with the intro-
duction of a new drug is a good in-
dication of a history of a disease.
Exclusion of any organic causes is
recommended, especially if the
symptoms are new or if they are as-
sociated with melaena, anaemia or
with weight loss. However, usually
no definite organic cause is found
and the symptoms may be consid-
ered functional.
Different types of constipation
Functional constipation can be clas-
sified according to the symptoms
and findings as follows, slow intesti-
nal transit, pelvic floor functional
disturbance (outlet obstruction,
paradoxical puborectalis syndrome,
anismus) or irritable bowel syn-
drome (1, 2, 3, 4). In practice, the
classification is useful even though
the symptoms in many patients in-
clude features of several types of
constipation. Patient history and
clinical examination combined with
sigmoidoscopy and laboratory tests
such as haemoglobin, fasting blood
sugar, thyroid stimulating hormone,
blood creatinine, and blood calcium
are usually adequate. Examination
of the transit time and defaecogra-
phy are occasionally necessary, but
anal manometry and neurophysio-
logical examinations of the anal area
are very seldom required.
The frequency of bowel move-
ments in patients with constipation
of the functional slow transit type is
once a week or less. The stool is too
hard, the response to conventional
treatment is poor and gradually the
urge to defaecate decreases. Pro-
longed intestinal transit time can be
established by a transit time exami-
nation which consists of the patient
swallowing small X-ray positive
pieces of plastic which remain undi-
gested in the digestive tract. In the
atonic large intestine (colonic iner-
tia) the pieces remain in the ascend-
ing colon or in the neighbourhood
of the colon, whereas in outlet ob-
struction due to pelvic floor muscu-
lar dysfunction they remain in the
sigmoid colon and in the rectum.
Patients with constipation char-
acterised by pelvic floor dysfunction
have difficulties with the evacuation
of the faeces, they frequently need to
strain at stool, faecal impaction oc-
curs in the rectum and the frequency
of elimination may be normal, or
higher or lower than normal. The
intestinal transit time is normal or
slightly prolonged. In examining
such cases, defaecography (contrast
study), anorectal manometry or elec-
tromyography (EMG) may be used.
Defaecography can detect whether
the patient’s anal sphincter, and es-
pecially the puborectal muscle, is
not relaxing in the normal way dur-
ing defaecation. Similarly, manome-
try and EMG can detect paradoxical
constriction of the anal sphincter
during defaecation. The studies are
situation-sensitive and the results are
not particularly specific. Any cases
of rectocele, enterocele or prolapse
of the rectal mucosa will also be de-
tected by defaecography.
Constipation is the dominant
symptom in some patients suffering
from irritable bowel syndrome. The
symptoms typically include abdomi-
nal pain and swelling, difficulty in
evacuating the bowel, inspissated
and pelleted stools and occasional
bouts of small-volume diarrhoea. 
Treatment of constipation
Proper guidelines for a lifestyle and
a correct diet are the basis of treat-
ment (Table 2). The guidelines for a
lifestyle should consist of a review
of and training in the habits and
event of evacuation. It would be
beneficial to include intake of addi-
tional fibre and increased consump-
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Constipation occurs in 2–20% of the population. It is most common in women and its occurrence
increases with age. The complications consist of hard stool, decreased frequency of elimination and
occasionally difficult evacuation of the faeces. According to the most commonly used criteria, the
defining characteristics of constipation are: a frequency of elimination less than 3 times a week,
hard stool, often straining at stool, the symptoms occurring during at least 12 weeks in one year.
International (1) survey have been published recently on the diagnosis and treatment of constipa-
tion.
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tion of water in the dietary advice.
In addition to fibre, medicinal fibre
(bulk laxatives) may be used. Fibre
increases the faecal mass and accel-
erates the intestinal transit time. Our
normal nutrition usually contains
15–20 grams of fibre per day,
whereas the recommended amount
is 25–35 grams per day. Additional
fibre is obtained by increasing the
consumption of greens, root vegeta-
bles, fruit, wholemeal products and
bran, or the daily use of 10–20
grams of fibre preparations available
from the pharmacy. This treatment
is usually adequate for patients with
constipation associated with irritable
bowel syndrome and even for pa-
tients with functional outlet obstruc-
tion. The increase of fibre in the diet
causes flatulence in many people
and, as a result, an adequate
amount of fibre is often not
achieved in the diet. For patients
with severe constipation of the slow
transit type, additional fibre in the
diet is not usually an adequate mea-
sure.
Mainly osmotically active laxa-
tives such as lactulose, lactitol, milk
of magnesia and polyethylene glycol
(macrogol) would be appropriate for
use when additional fibre intake
alone is not sufficient. Lactulose and
lactitol are disaccharides which are
not degraded in the intestine until
after the effect of bacteria in the
large intestine; they reduce the in-
testinal pH and accumulate liquid in
the large intestine. Fast-acting lactu-
lose and lactitol appropriately com-
plement the laxative effect of fibres.
Lactulose and lactitol also cause
flatulence, which restricts their use,
and their efficacy is often not
enough for patients with severe con-
stipation. Milk of magnesia does not
generally cause flatulence and is ap-
propriate for use especially in addi-
tion to fibre treatment. There is a
risk of hypermagnaesemia in pa-
tients with renal failure.
Macrogol is an osmotic laxative
with insignificant absorption from
the intestine (5). For nearly 20 years
it has been used as a substance pro-
moting evacuation of the large intes-
tine in preparation for a coloscopy.
In recent years, it has also been in-
troduced in the treatment of chronic
constipation (5). The substance is ef-
fective and clinical studies have also
found it safe to use (6). Macrogol is
especially recommended for use in
patients with severe slow transit
constipation. Adverse reactions may
nevertheless include flatulence, nau-
sea, excessive diarrhoea and associ-
ated dryness and faecal inconti-
nence. Unfortunately, the drug is
rather costly and is not refundable
by health insurance in Finland.
Laxatives with intestinal stimula-
tion include senna, bisacodyl and
sodium picosulphate preparations.
In previous studies, they have been
suspected of having caused damage
to the intestinal nerves (7) and being
capable of causing intestinal slug-
gishness with long-term use. In later
studies, it has not been possible to
obtain definite confirmation of this
(8), but caution is still exercised in
the long-term use of stimulating lax-
atives. When they are used, the in-
testinal evacuation may be powerful
and even painful. Sodium picosul-
phate is used by practical oral ad-
ministration in the form of drops al-
lowing individual dose adjustment.
In the severe slow transit type of
constipation, macrogol, if necessary
together with a stimulating laxative
is  often the most effective treat-
ment.
Prokinetic cisapride accelerates
the large intestinal transit time and
relieves the constipation (9). Cis-
apride may nevertheless also cause
painful spasms. It has subsequently
been found to have complex interac-
tions with certain drugs and its use
is no longer recommended. In Fin-
land at present, there are no proki-
netic drugs in use which would ef-
fectively increase the large intestine
motility. A new 5-hydroxytrypta-
mine (5-HT4) receptor agonist,
tegaserod has been found to be espe-
cially beneficial in the treatment of
patients with irritable bowel syn-
drome of the constipation type.
Table 1 .  General  causes of
const ipat ion 
Life-style
Insufficient consumption of
fibres
Insufficient consumption of 
water
Lack of exercise
Unnecessary inhibition of the 
defaecation reflex
Medication
Calcium-channel blockers
Diuretics
Neuroleptics
Antidepressants
Iron supplements
Statins
Anti-inflammatory analgesics
Opioids 
Anticholinergic agents
Antacids
Metabolic and endocrine causes
Hypothyroidism
Diabetes
Dehydration
Hypercalcaemia
Hyperkalaemia
Uraemia
Neurological causes
Palsy of CNS origin
Spinal cord injuries
Multiple sclerosis
Parkinson’s disease
Causes related to the intestine
Structural causes
intestinal obstructions: neo-
plasms, strictures of varying
etiology, diseases of the
anal area
Functional causes
spastic pelvic floor syn-
drome (outlet obstruction),
slow intestinal transit,
Irritable bowel syndrome
Table 2.  Treatment of  const i-
pat ion
Mild constipation
increased intake of fibre
an extra 2 glasses of water after
every meal
use of bulk laxatives and/or lac-
tulose or lactitol
Irritable bowel syndrome and consti-
pation
use of a bulk laxative and di-
etary advice
Pelvic floor dysfunction syndrome
training in defaecation physiol-
ogy
use of a bulk laxative
biofeedback treatment
Severe slow transit constipation
macrogol and stimulating 
laxatives when needed
biofeedback treatment
surgery
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Biofeedback treatment is aimed
at relaxing the pelvic floor muscles
and restoring their normal function
in association with defaecation. The
treatment has been found to be of
benefit especially to patients suffer-
ing from pelvic floor dysfunction
(10), even though the symptoms
tend to recur gradually after discon-
tinuation of treatment (11). Treat-
ment is given by physiotherapists fa-
miliar with this type of treatment.
This is recommended in patients
well motivated towards treatment,
but following a review of the defae-
cation event and associated medical
therapy the results appear inade-
quate.
Surgical treatment, usually colec-
tomy and ileorectal anastomosis,
may be considered in patients with
constipation of the slow transit type
with inadequate response to other
treatment.
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Various gastrointestinal complaints
are among the commonest of the
medical symptoms. For example, an
estimated 20-40% of the population
complains from time to time of up-
per abdominal discomfort. Abdomi-
nal complaints in the population are
common, and distinguishing adverse
drug reactions (ADRs) from abdom-
inal dysfunction such as nausea, in-
digestion, constipation and diar-
rhoea may consequently be difficult,
if not impossible, in practice. Due to
the high incidence of gastrointestinal
symptoms, under-reporting of the
symptoms may occur, especially
when the reaction is not unexpected-
ly intense or severe. However, if
there is a known explicit or suspect-
ed mechanism which gives rise to
the suspicion that the effect is, in
fact, that of a medicinal substance,
it becomes considerably easier to as-
sume or actually to indicate and re-
port the causal relationship. The
number of alimentary tract related
adverse reactions reported to the
National Agency for Medicines be-
tween 1973 and end of June 2003
was about 2 000, which is approxi-
mately 10 % of all ADRs reported
in the country.
This is a summing-up of the
most common adverse reactions, the
mechanisms of which are known, ei-
ther in part of fully, and the implica-
tions of which are the most serious
ones even for the patient. These are
the criteria by which the adverse re-
actions reported have mainly been
defined, as various cases of gastroin-
testinal bleeding, lesions and drug-
induced infections or exacerbations
of them. In general, the alimentary-
tract-related adverse reactions are,
by percentage, spread over the vari-
ous drug groups similarly to the de-
scription given in the survey pub-
lished in the issue 3/2003 of the
journal TABU. The most common
salient exceptions occur in the case
of antimicrobials (34% vs. 28%)
and preparations used for the treat-
ment of diseases of the musculo-
skeletal system (18% vs. 11%), the
gastrointestinal adverse reactions of
which are more numerous than the
relative amount of all ADR reports
related to these drug groups (Table).
The number of cases of suspected
drug-induced gastrointestinal bleed-
ing was 240 over a period of 30
years. The number includes cases of
haematemesis as well as bloody di-
arrhoea. Furthermore, a total of 20
cases of bleeding ulcers, perforated
peptic ulcers and internal abdominal
bleeding have been reported. In 21
cases bleeding was fatal. The over-
whelming majority of cases of bleed-
ing has been reported in association
with the use of broad spectrum
penicillins, i.e. amoxicillin and other
ampicillin derivatives (28% of the
total), but just the number of re-
ports associated with the use of phe-
noxymethylpenicillin make up 20%
of the total, i.e. nearly half of the re-
ported cases are associated with
penicillin derivatives. The most com-
Gastrointestinal adverse drug reactions in Finland
in 1973–2003 
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Gastrointest inal  adverse react ions reported to the ADR register  
during 1973–2003,  divided by drug groups 
percentage 
of reports, %
Anti-infectives for systemic use 34
Musculo-skeletal system 18
Cardiovascular system 14
Nervous system 14
Alimentary tract and metabolism 5
Genito-urinary system and sex hormones 4
Respiratory system 3
Blood and blood forming organs 2
Antineoplastic and immunomodulating agents 2
Radiopharmaceuticals 2
Dermatologicals 1
Hormonal preparations (excl. sex hormones) 1
Antiparasitic products, insecticides and repellents 1
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monly used term of all has been
melaena, and only 38 reports refer
specifically to Clostridium difficile
infection, pseudomembranous colitis
or haemorrhagic colitis. It is pre-
sumed nevertheless that the cause in
the majority of cases associated with
the use of ambicillin derivatives and
cefalosporins has been pseudomem-
branous colitis associated with
Clostridium difficile. It is interesting
to notice, indeed, that cephalo-
sporins, and cefuroxime axetil in
particular, were the most important
cause of Clostridium difficile-in-
duced diarrhoea reported in the ma-
terial compiled during the 1990’s
from the hospitals of Helsinki.
Inhibition of prostaglandin syn-
thesis associated with the mecha-
nism of action of anti-inflammatory
analgesics and, in particular, the re-
duction induced by anti-inflammato-
ry analgesics in the synthesis of
prostaglandin E2, which protects the
abdominal mucous membrane, is a
characteristic predisposing factor for
peptic ulceration, perforated peptic
ulcers and gastrointestinal bleeding.
Indeed, about a third of the reported
cases of gastrointestinal bleeding, ul-
cerations and perforations have been
associated with the continuous use
of high doses NSAIDs. 
Antimicrobials and NSAIDs were
suspected to cause over 75 % of GI
bleedings reported to NAM (Fig).
Strangely enough, heparin deriva-
tives and warfarin, which merely by
their mechanism of action are fac-
tors predisposing to bleeding, have
only been the subject of 12 reports
associated with gastrointestinal
bleeding. Equally, there are only 4
reports on anti-cancer drugs which,
by their mechanism of action, pre-
dispose the patient to mucous mem-
brane damage.
The most common adverse reac-
tions reported at the end of the
1970’s and beginning of the 1980’s
were oesophageal corrosion and in-
flammation, nearly 100 cases of
which were reported to have been
associated especially with the use of
both tetracycline and doxycycline.
During the same period, about 40
reports were received regarding the
oesophageal damage caused by an
anticholinergic agent, emepronium,
used to abate the increased need for
micturition and improve urinary re-
tention. The cases were most com-
monly associated with the intake of
the drug with inadequate amounts
of liquid. Following the identifica-
tion of the adverse reaction and the
associated cause, the reporting of
the reactions ceased in practice in
the mid-1980’s.
Ten cases of bleeding or oeso-
phageal ulceration associated with
the use of drugs for the treatment of
cardiovascular diseases have been
reported. The relatively high per-
centage (14%) of reports within this
group of medicinal substances in
comparison with the total number
of reports is mainly explained by the
general symptoms (abdominal pain,
nausea, diarrhoea, vomiting) and
gingival hyperplasia induced by cal-
cium antagonists. Gastrointestinal
symptoms associated with medicinal
substances affecting the nervous sys-
tem are often linked with nausea,
vomiting and diarrhoea induced by
antidepressant agents. Another well
known and commonly reported ad-
verse reaction is abdominal pain as-
sociated with the direct stimulation
of the gastrointestinal motilin recep-
tors and caused by macrolide antibi-
otics, i.e. erythromycin derivatives,
and also nausea reported in associa-
tion with the use of tetracycline.
It should be stated, by way of
conclusion, that despite the wide
spread occurrence of gastrointestinal
symptoms in the population irre-
spective of whether drugs are used
or not, the reports on adverse reac-
tions related to gastrointestinal
symptoms cover about a tenth of all
the reports in the ADR register at
the National Agency. The majority
of the suspected adverse reactions
have been associated with abdomi-
nal pain interpreted as functional,
but among the most serious reac-
tions, over 10% of the total number
of reports were of various types of
gastrointestinal bleeding associated
with the use of drugs. Approximate-
ly 75% of bleeding complications
were reported during the use of
broad spectrum penicillins, phe-
noxymethylpenicillin and anti-in-
flammatory analgesics. Nevertheless,
this should not lead us into drawing
wrong conclusions when bleeding
complications associated with other
medications are suspected.
27 %
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